Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines
Related Experiment Video
Updated: Jun 29, 2026
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Jens Wagenblast1, Mehran Baghi, Christoph Arnoldner
1ENT Department, Frankfurt University Medical School, University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Germany. Jens.Wagenblast@kgu.de
Purpose:
Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade) in combination with cetuximab in squamous cell carcinoma cell lines (SCC).
Methods:
Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay.
Results:
Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P < 0.042), and the activity was further significantly enhanced by the addition of cetuximab (P < 0.043).
Conclusions:
Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.
